Intravenous thrombolysis for acute ischaemic stroke: Effective blood pressure control matters

International Journal of Stroke

Volumn 6, Issue 2, 2011, Pages 125-127

  Tsivgoulis, Georgios ^a   Kotsis, Vasilios ^b   Giannopoulos, Sotirios ^c  

^a DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

^b ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^c UNIVERSITY OF IOANNINA   (Greece)

Author keywords

Blood pressure; Intracranial haemorrhage; Outcome; RtPA; Stroke; Thrombolysis

Indexed keywords

ALTEPLASE; LABETALOL; NICARDIPINE;

BLOOD CLOT LYSIS; BRAIN ISCHEMIA; DISEASE CONTROL; DRUG EFFICACY; HUMAN; HYPERTENSION; NOTE; PREDICTOR VARIABLE; PRIORITY JOURNAL; STROKE; TREATMENT OUTCOME;

BLOOD PRESSURE; CLINICAL TRIALS AS TOPIC; FIBRINOLYTIC AGENTS; HUMANS; HYPERTENSION; INJECTIONS, INTRAVENOUS; PRACTICE GUIDELINES AS TOPIC; STROKE; THROMBOLYTIC THERAPY; TISSUE PLASMINOGEN ACTIVATOR;

EID: 79952303726     PISSN: 17474930     EISSN: 17474949     Source Type: Journal    
DOI: 10.1111/j.1747-4949.2010.00570.x     Document Type: Note

References (31)

1. Haley EC Jr, Levy DE, Brott TG et al. Urgent therapy for stroke. Part II. Pilot study of tissue plasminogen activator administered 91-180 minutes from onset. Stroke 1992; 23:641-5.
2. Brott TG, Haley EC, Levy DE et al. Urgent therapy for stroke. Part I. Pilot study of tissue plasminogen activator administered within 90 minutes. Stroke 1992; 23:632-40.
3. Levy DE, Brott TG, Haley EC Jr et al. Factors related to intracranial hematoma formation in patients receiving tissue-type plasminogen activator for acute ischemic stroke. Stroke 1994; 25:291-7.
4. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995; 333:1581-7.
5. Adams HP Jr, Adams RJ, Brott T et al. Guidelines for the early management of patients with ischemic stroke: a scientific statement from the Stroke Council of the American Stroke Association. Stroke 2003; 34:1056-83.
6. European Stroke Organisation (ESO) Executive Committee; ESO Writing Committee. Guidelines for management of ischaemic stroke and transient ischaemic attack 2008. Cerebrovasc Dis 2008; 25:457-507.
7. Leonardi-Bee J, Bath PM, Phillips SJ, Sandercock PA, IST Collaborative Group. Blood pressure and clinical outcomes in the International Stroke Trial. Stroke 2002; 33:1315-20.
8. Hill MD, Buchan AM, Canadian Alteplase for Stroke Effectiveness Study (CASES) Investigators. Thrombolysis for acute ischemic stroke: results of the Canadian Alteplase for Stroke Effectiveness Study. CMAJ 2005; 172:1307-12.
9. Lindsberg PJ, Soinne L, Roine RO et al. Community-based thrombolytic therapy of acute ischemic stroke in Helsinki. Stroke 2003; 34:1443-9.
10. Oliveira-Filho J, Silva SC, Trabuco CC, Pedreira BB, Sousa EU, Bacellar A. Detrimental effect of blood pressure reduction in the first 24 hours of acute stroke onset. Neurology 2003; 61:1047-51.
11. Castillo J, Leira R, García MM, Serena J, Blanco M, Dávalos A. Blood pressure decrease during the acute phase of ischemic stroke is associated with brain injury and poor stroke outcome. Stroke 2004; 35:520-6.
12. Katzan IL, Furlan AJ, Lloyd LE et al. Use of tissue-type plasminogen activator for acute ischemic stroke: the Cleveland area experience. JAMA 2000; 283:1151-8.
13. Lopez-Yunez AM, Bruno A, Williams LS, Yilmaz E, Zurrú C, Biller J. Protocol violations in community-based rTPA stroke treatment are associated with symptomatic intracerebral hemorrhage. Stroke 2001; 32:12-16.
14. Albers GW, Bates VE, Clark WM, Bell R, Verro P, Hamilton SA. Intravenous tissue-type plasminogen activator for treatment of acute stroke: the Standard Treatment with Alteplase to Reverse Stroke (STARS) Study. JAMA 2000; 283:1145-50.
15. Tanne D, Bates VE, Verro P et al. Initial clinical experience with IV tissue plasminogen activator for acute ischemic stroke: a multicenter survey. The t-PA Stroke Survey Group. Neurology 1999; 53:424-7.
16. Nadeau JO, Shi S, Fang J et al. TPA use for stroke in the Registry of the Canadian Stroke Network. Can J Neurol Sci 2005; 32:433-9.
17. Katzan IL, Hammer MD, Furlan AJ, Hixson ED, Nadzam DM, Cleveland Clinic Health System Stroke Quality Improvement Team. Quality improvement and tissue-type plasminogen activator for acute ischemic stroke: a Cleveland update. Stroke 2003; 34:799-800.
18. Bravata DM, Kim N, Concato J, Krumholz HM, Brass LM. Thrombolysis for acute stroke in routine clinical practice. Arch Intern Med 2002; 162:1994-2001.
19. Tsivgoulis G, Frey JL, Flaster M et al. Pre-tissue plasminogen activator blood pressure levels and risk of symptomatic intracerebral hemorrhage. Stroke 2009; 40:3631-4.
20. Meretoja A, Putaala J, Tatlisumak T et al. Off-label thrombolysis is not associated with poor outcome in patients with stroke. Stroke 2010; 41:1450-8.
21. Larrue V, von Kummer RR, Müller A, Bluhmki E. Risk factors for severe hemorrhagic transformation in ischemic stroke patients treated with recombinant tissue plasminogen activator: a secondary analysis of the European-Australasian Acute Stroke Study (ECASS II). Stroke 2001; 32:438-41.
22. Tanne D, Kasner SE, Demchuk AM et al. Markers of increased risk of intracerebral hemorrhage after intravenous recombinant tissue plasminogen activator therapy for acute ischemic stroke in clinical practice: the Multicenter rt-PA Stroke Survey. Circulation 2002; 105:1679-85.
23. Ahmed N, Wahlgren N, Brainin M et al. Relationship of blood pressure, antihypertensive therapy, and outcome in ischemic stroke treated with intravenous thrombolysis. Retrospective analysis from safe implementation of thrombolysis in Stroke - International Stroke Thrombolysis Register (SITS-ISTR). Stroke 2009; 40:2442-9.
24. Wahlgren N, Ahmed N, Eriksson N et al. Multivariable analysis of outcome predictors and adjustment of main outcome results to baseline data profile in randomized controlled trials: Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST). Stroke 2008; 39:3316-22.
25. Tsivgoulis G, Saqqur M, Sharma VK et al. CLOTBUST Investigators. Association of pretreatment blood pressure with tissue plasminogen activator-induced arterial recanalization in acute ischemic stroke. Stroke 2007; 38:961-6.
26. Sjögren LS, Doroudi R, Gan L, Jungersten L, Hrafnkelsdóttir T, Jern S. Elevated intraluminal pressure inhibits vascular tissue plasminogen activator secretion and downregulates its gene expression. Hypertension 2000; 35:1002-8.
27. Ulfhammer E, Ridderstråle W, Andersson M, Karlsson L, Hrafnkelsdóttir T, Jern S. Prolonged cyclic strain impairs the fibrinolytic system in cultured vascular endothelial cells. J Hypertens 2005; 23:1551-7.
28. Nogueira RG, Liebeskind DS, Sung G, Duckwiler G, Smith WS, MERCI, Multi MERCI Writing Committee. Predictors of good clinical outcomes, mortality, and successful revascularization in patients with acute ischemic stroke undergoing thrombectomy: pooled analysis of the Mechanical Embolus Removal in Cerebral Ischemia (MERCI) and Multi MERCI Trials. Stroke 2009; 40:3777-83.
29. Molina CA, Alexandrov AV, Demchuk AM et al. CLOTBUST Investigators. Improving the predictive accuracy of recanalization on stroke outcome in patients treated with tissue plasminogen activator. Stroke 2004; 35:151-6.
30. Demchuk AM, Tanne D, Hill MD et al. Predictors of good outcome after intravenous tPA for acute ischemic stroke. Neurology 2001; 57:474-80.
31. Martin-Schild S, Hallevi H, Albright KC et al. Aggressive blood pressure-lowering treatment before intravenous tissue plasminogen activator therapy in acute ischemic stroke. Arch Neurol 2008; 65:1174-8.